Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) will be releasing its earnings data after the market closes on Tuesday, May 7th. Analysts expect Ligand Pharmaceuticals to post earnings of $1.13 per share for the quarter. Ligand Pharmaceuticals has set its FY 2024 guidance at 4.250-4.750 EPS and its FY24 guidance at $4.25 to $4.75 EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last announced its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.55. Ligand Pharmaceuticals had a net margin of 37.80% and a return on equity of 11.98%. The firm had revenue of $28.10 million during the quarter, compared to analysts’ expectations of $24.54 million. On average, analysts expect Ligand Pharmaceuticals to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.
Ligand Pharmaceuticals Price Performance
NASDAQ:LGND opened at $73.90 on Monday. The business’s 50-day moving average is $74.53 and its two-hundred day moving average is $68.76. The firm has a market capitalization of $1.31 billion, a PE ratio of 26.87 and a beta of 1.01. Ligand Pharmaceuticals has a 12 month low of $49.24 and a 12 month high of $94.57.
Wall Street Analysts Forecast Growth
Read Our Latest Research Report on LGND
Insider Transactions at Ligand Pharmaceuticals
In related news, Director Stephen L. Sabba sold 1,893 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $74.30, for a total value of $140,649.90. Following the completion of the transaction, the director now owns 28,926 shares of the company’s stock, valued at $2,149,201.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 10.40% of the company’s stock.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.
Further Reading
- Five stocks we like better than Ligand Pharmaceuticals
- Profitably Trade Stocks at 52-Week Highs
- Brinker International Heats Up on Spicy Earnings Beat and Raise
- 3 REITs to Buy and Hold for the Long Term
- Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon
- How to Start Investing in Real Estate
- Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.